Stivarga regorafenib: Phase III data

Top-line data from the double-blind, international Phase III RESORCE trial in about 573 patients with unresectable HCC

Read the full 179 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE